Keros Therapeutics, Inc. (KROS) Spending and interest coverage
- R&D / revenue · 12 months: Value 505.26%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 152.30%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 505.26% | Research and development expense / revenue. Period ending 2026-06-30. $75.86M ÷ $15.01M × 100 ≈ 505.26% |
| Stock-based compensation / revenue · 12 months | 152.30% | Share-based compensation / revenue. Period ending 2026-06-30. $22.87M ÷ $15.01M × 100 ≈ 152.30% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 75.86M USD | Research and Development Expense |
| Revenue | 15.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 22.87M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -101.47M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $75.86M | $15.01M | $22.87M | $-101.47M | (m) | 505.26% | 152.30% | (m) | (m) |
| 2026-03-31 | $97.03M | $33.18M | $26.03M | $-110.35M | (m) | 292.42% | 78.45% | (m) | (m) |
| 2025-12-31 | $129.64M | $244.06M | $28.70M | $67.57M | (m) | 53.12% | 11.76% | (m) | (m) |
| 2025-09-30 | $157.36M | $246.72M | $30.59M | $43.59M | (m) | 63.78% | 12.40% | (m) | (m) |
| 2025-06-30 | $187.07M | $232.84M | $35.42M | $312.00K | (m) | 80.34% | 15.21% | (m) | (m) |
| 2025-03-31 | $184.08M | $214.71M | $35.66M | $-10.31M | (m) | 85.73% | 16.61% | (m) | (m) |
| 2024-12-31 | $173.63M | $3.55M | $34.87M | $-210.83M | (m) | 4890.96% | 982.31% | (m) | (m) |
| 2024-09-30 | $165.49M | $651.00K | $33.00M | $-204.03M | (m) | 25421.04% | 5068.51% | (m) | (m) |
| 2024-06-30 | $150.41M | $271.00K | $32.89M | $-188.66M | (m) | 55500.37% | 12136.53% | (m) | (m) |
| 2024-03-31 | $142.43M | $234.00K | $31.15M | $-179.56M | (m) | 60865.38% | 13310.26% | (m) | (m) |
| 2023-12-31 | $135.26M | $151.00K | $28.76M | $-169.94M | (m) | 89574.83% | 19048.34% | (m) | (m) |
| 2023-09-30 | $122.63M | $8.00K | $26.18M | $-155.45M | (m) | 1532900.00% | 327312.50% | (m) | (m) |
| 2023-06-30 | $109.53M | (m) | $22.23M | $-140.14M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $100.28M | (m) | $19.98M | $-129.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $87.27M | $0.00 | $18.68M | $-114.79M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $81.23M | $20.00M | $17.23M | $-87.70M | (m) | 406.16% | 86.16% | (m) | (m) |
| 2022-06-30 | $75.02M | $20.00M | $15.56M | $-79.92M | (m) | 375.12% | 77.81% | (m) | (m) |
| 2022-03-31 | $61.73M | (m) | $13.62M | $-64.73M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $55.14M | $20.10M | $11.72M | $-56.37M | (m) | 274.34% | 58.32% | (m) | (m) |
| 2021-09-30 | $45.98M | $100.00K | $9.95M | $-64.80M | (m) | 45984.00% | 9949.00% | (m) | (m) |
| 2021-06-30 | $39.55M | $100.00K | $8.29M | $-56.55M | (m) | 39547.00% | 8289.00% | (m) | (m) |
| 2021-03-31 | $36.83M | (m) | $6.58M | $-51.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $33.86M | $0.00 | $4.10M | $-46.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $17.38M | $10.00M | $59.00K | $-10.56M | (m) | 173.79% | 0.59% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |